2023-11-14T15:09:35-06:00 2022-12-31 260794367 UHY ADVISORS MID-ATLANTIC MD INC 8601 ROBERT FULTON DRIVE SUITE 210 COLUMBIA MD 21046 990 2022-01-01 452410498 RX-360 INTERNATIONAL PHARMACEUTICAL SUPPLY CHAIN CONSORTIUM RX-3 2155433846 PO BOX 40931 PHILADELPHIA PA 19107 JIM FRIES CEO 3017109399 2023-11-14 1 JIM FRIES 999009999 0 KATSIARYNA VASILIEV P02167272 4107205220 2023-11-14 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z JIM FRIES PO BOX 40931 PHILADELPHIA PA 19107 3588442 0 X WWW.RX-360.ORG X 2009 PA THE ORGANIZATION'S MISSION IS TO PROTECT PATIENT SAFETY BY SHARING INFORMATION AND DEVELOPING PROCESSES RELATED TO THE INTEGRITY OF THE HEALTHCARE SUPPLY CHAIN AND THE QUALITY OF MATERIALS WITHIN THE SUPPLY CHAIN. 18 18 17 0 0 0 15000 0 2928244 3586487 0 0 679 1955 2943923 3588442 0 0 0 0 762534 1112520 0 0 0 1291310 1875643 2053844 2988163 890079 600279 2136683 3000257 895501 1158796 1241182 1841461 THE ORGANIZATION'S MISSION IS TO PROTECT PATIENT SAFETY BY SHARING INFORMATION AND DEVELOPING PROCESSES RELATED TO THE INTEGRITY OF THE HEALTHCARE SUPPLY CHAIN AND THE QUALITY OF MATERIALS WITHIN THE SUPPLY CHAIN. 0 0 ENHANCING THE SECURITY OF THE PHARMACEUTICAL SUPPLY CHAIN THROUGH TWO AUDIT PROGRAMS AND RESEARCH PROGRAMS. THE RX-360 AUDIT SHARING PROGRAM ALLOWS RX-360 TO LICENSE SUPPLIER QUALITY AUDITS CONDUCTED BY RX-360 IN A CONFIDENTIAL MANNER. THE RX-360 JOINT AUDITING PROGRAM ALLOWS RX-360 TO CONDUCT JOINT CONDUCT JOINT QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES. RX-360 ALSO ANALYZES NEW LEGISLATION, REGULATIONS, STANDARDS, AND OTHER DEVELOPMENTS THAT IMPACT THE PHARMACEUTICAL SUPPLY CHAIN, AND MAKES THIS INFORMATION AVAILABLE TO RX-360 MEMBERS AND THE PUBLIC VIA RX-360'S WEBSITE. 0 0 0 1 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 8 0 1 17 1 0 0 0 0 0 0 0 0 X 18 18 0 0 0 0 1 1 1 1 1 0 0 0 1 1 1 0 1 1 0 0 X JIM FRIES 2155433846 PO BOX 40931 PHILADELPHIA PA 19107 REGGIE JACKSON DIRECTOR 2.00 X 0 0 0 TOM LUPO DIRECTOR 2.00 X 0 0 0 ERIC BERG DIRECTOR 2.00 X 0 0 0 MARC EGAN DIRECTOR 2.00 X 0 0 0 CHRISTIAN LIEBL DIRECTOR 2.00 X 0 0 0 STEPHAN PEETERS DIRECTOR 2.00 X 0 0 0 ISABELLE QUINTARD DIRECTOR 2.00 X 0 0 0 ANTHONY ZOOK DIRECTOR 2.00 X 0 0 0 GUY VILLAX DIRECTOR 2.00 X 0 0 0 BRIAN URBAN DIRECTOR 2.00 X 0 0 0 ANTHONY DAMAS DIRECTOR 2.00 X 0 0 0 BILL CAMPAGNA DIRECTOR 2.00 X 0 0 0 JENNIFER STONE DIRECTOR 2.00 X 0 0 0 LUCY CABRAL CHAIR 3.00 X X 0 0 0 TIM VALKO PAST CHAIR 3.00 X X 0 0 0 ROB WELSH VICE CHAIR 3.00 X X 0 0 0 SCOTT KAMMER TREASURER 3.00 X X 0 0 0 KATHLEEN SILVA SECRETARY 2.00 X X 0 0 0 JIM FRIES CEO 40.00 X 290440 0 3627 JAYE GREEN HEAD OF AUDIT OPERATIONS 40.00 X 114402 0 10558 404842 0 14185 2 0 1 0 YOUR PART TIME CONTROLLER 1500 WALNUT STREET SUITE 1200 PHILADELPHIA PA 19102 OUTSOURCED ACCOUNTING SERVICES 181765 STEPTOE & JOHNSON PLLC 400 WHITE OAKS BLVD BRIDGEPORT WV 26330 LEGAL SERVICE 109296 2 LICENSED FEES 900099 1909250 1909250 MEMBERSHIP DUES 900099 1128034 1128034 SPONSORED AUDIT FEES 900099 335203 335203 LICENSED ADMINISTRATIV 900099 214000 214000 3586487 CREDIT CARD REWARDS 900099 1955 1955 1955 3588442 3588442 0 0 X 419025 586772 3637 26591 76495 118228 199120 925736 104790 44924 131786 33149 89757 106699 13924 77469 BAD DEBTS 17370 DUES AND SUBSCRIPTIONS 12691 2988163 1403641 2092509 612277 532436 84841 142135 117998 20729 31424 97269 4500 135908 2136683 3000257 194392 70599 701109 960838 0 127359 895501 1158796 X 1241182 1841461 1241182 1841461 2136683 3000257 600279 0 X X 0 1 X 1 0 1 1 0 18845 4997 13848 99153 15732 83421 97269 OFFICE LEASE LIABILITY 127359 127359 X 3588442 0 3588442 0 3588442 2988163 0 2988163 0 2988163 PART X, LINE 2: THE INCOME TAX POSITIONS TAKEN BY RX-360 FOR ANY YEAR OPEN UNDER THE VARIOUS STATUTES OF LIMITATIONS ARE THAT RX-360 CONTINUES TO BE EXEMPT FROM INCOME TAXES AND THAT THEY HAVE PROPERLY REPORTED UNRELATED BUSINESS INCOME THAT IS SUBJECT TO INCOME TAXES. RX-360 BELIEVES THAT THERE ARE NO TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN THAT WOULD SIGNIFICANTLY INCREASE UNRECOGNIZED TAX LIABILITIES WITHIN 12 MONTHS OF THE REPORTING DATE. NONE OF RX-360'S FEDERAL OR STATE INCOME TAX RETURNS ARE CURRENTLY UNDER EXAMINATION. 1 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 PROGRAM SERVICES - AUDITS QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES 140141 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES - AUDITS QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES 555483 LATIN AMERICA 0 0 PROGRAM SERVICES - AUDITS QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES 12135 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES - AUDITS QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES 1995 0 0 0 0 0 0 709754 0 709754 0 0 0 0 0 0 PART I, LINE 3: ACCRUAL METHOD IS USED TO ACCOUNT FOR EXPENDITURES. PART III ACCOUNTING METHOD: 1 X X X 0 0 0 JIM FRIES CEO 221800 0 68640 0 0 0 2281 0 1346 0 294067 0 0 0 PART I, LINE 3 COMPENSATION FOR THE CEO IS EVALUATED ON AN ANNUAL BASIS BY THE COMPENSATION COMMITTEE AND THE CHAIR OF THE BOARD OF DIRECTORS. COMPENSATION IS BASED ON THE LEVEL OF SKILL REQUIRED FOR THE POSITION, AN EVALUATION OF THE INDIVIDUAL'S ACHIEVEMENT, AND A COMPARISON OF COMPENSATION TO SIMILAR POSITIONS IN THE NON-PROFIT INDUSTRY. THE DETERMINATION OF THE COMPENSATION IS DOCUMENTED BY A COMPENSATION AGREEMENT EXECUTED BY THE CHAIR OF THE BOARD OF DIRECTORS, THE CHAIR OF THE COMPENSATION COMMITTEE, AND THE CEO. FORM 990, PART VI, SECTION A, LINE 6 ANY LEGAL ENTITY MAY BECOME A MEMBER OF RX-360 IF THE FOLLOWING CRITERIA IS MET: 1 - ITS ACTIVITIES RELATE TO THE RESEARCH, DEVELOPMENT, OR MANUFACTURE OF PHARMACEUTICAL OR BIOTECHNOLOGY PRODUCTS, INCLUDING RESEARCH-BASED PHARMACEUTICAL COMPANIES, GENERIC PHARMACEUTICAL COMPANIES, BIOTECHNOLOGY COMPANIES, AS WELL AS SUPPLIERS OF INGREDIENTS AND COMPONENTS OF PHARMACEUTICAL OR BIOTECHNOLOGY PRODUCTS AND SUPPLIERS OF SERVICES RELATING TO THE QUALITY OR SAFETY OF THE PHARMACEUTICAL OR BIOTECHNOLOGY SUPPLY (PROVIDERS OF AUDITING AND CONSULTING SERVICES ARE NOT ELIGIBLE FOR RX-360 MEMBERSHIP); 2 - IT AGREES TO PAY ANNUAL DUES AND ASSESSMENTS THAT ARE SET BY THE BOARD OF DIRECTORS; 3 - IF IT IS A GOVERNMENTAL UNIT OR QUASI-GOVERNMENTAL UNIT OR AN EDUCATIONAL INSTITUTION, IT DOES NOT INVOLVE THE LEGISLATIVE,JUDICIAL, OR EXECUTIVE BRANCHES OF GOVERNMENT, AND ALL STEPS WILL BE TAKEN BY THE ENTITY TO RESIST OR RESTRICT ANY ATTEMPT MADE BY THE LEGISLATIVE, JUDICIAL OR EXECUTIVE BRANCHES TO OBTAIN ACCESS TO RX-360 REPORTS OR CONFIDENTIAL INFORMATION, AND APPROPRIATE MECHANISMS ARE IN PLACE AT THE ENTITY TO ENSURE CONFIDENTIALITY AND TO PREVENT IMPROPER DISCLOSURE. THERE ARE THREE CLASSES OF RX-360 MEMBERS: ONE CLASS FOR MANUFACTURERS OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS WITH $500 MILLION (US DOLLARS) OR MORE IN WORLDWIDE GROSS REVENUE FROM SALES OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS AMONG AFFILIATED ENTITIES; ONE CLASS FOR MANUFACTURERS OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS WITH LESS THAN $500 MILLION (US DOLLARS) IN WORLDWIDE GROSS REVENUE FROM SALES OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS AMONG AFFILIATED ENTITIES AND CONTRACT MANUFACTURERS OF FINISHED DOSAGE FROM PHARMACEUTICAL AND BIOTCHNOLOGY PRODUCTS; AND, ONE CLASS FOR SUPPLIERS OF INGREDIENTS AND COMPONENTS OF SUCH PRODUCTS AND SUPPLIERS OF SERVICES. FORM 990, PART VI, SECTION A, LINE 7A ALL MEMBERS HAVE EQUAL VOTING RIGHTS IN ELECTIONS OF OFFICERS AND ALL MEMBERS ARE ELIGIBLE TO VOTE IN ELECTIONS OF THE BOARD OF DIRECTORS; HOWEVER, VOTING FOR BOARD MEMBERS IS DONE BY CATEGORY OF MEMBERSHIP. THE BYLAWS STATE THAT APPROXIMATELY 65% OF THE MEMBERSHIP OF THE BOARD SHALL BE COMPRISED OF REPRESENTATIVES OF LARGE FINISHED PRODUCT MANUFACTURERS, APPROXIMATELY 10% 0F THE MEMBERSHIP OF THE BOARD SHALL BE COMPRISED OF REPRESENTATIVES OF SMALL OR CONTRACT FINISHED PRODUCT MANUFACTURERS, AND APPROXIMATELY 25% SHALL BE COMPRISED OF REPRESENTATIVES OF SUPPLIERS. FORM 990, PART VI, SECTION A, LINE 7B THE BYLAWS OF RX-360 STATE THAT THE MEMBERS OF RX-360 HAVE THE POWER TO OVERRIDE ANY AMENDMENTS TO THE BYLAWS ADOPTED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B THE CEO FIRST REVIEWS THE 990. ONCE THE CEO IS SATISFIED THAT THE INFORMATION IS ACCURATE AND COMPLETE, IT IS FORWARDED TO THE CHAIR, VICE-CHAIR AND TREASURER FOR THEIR REVIEW. ONCE THEY ARE SATISFIED THAT THE INFORMATION IS ACCURATE AND COMPLETE, THE 990 IS FORWARDED TO THE FULL BOARD FOR REVIEW PRIOR TO SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C IT IS REVIEWED YEARLY UPON BYLAW REVIEW AND INSTALLATION OF ANNUAL BOARD (JANUARY). FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION FOR THE CEO IS EVALUATED ON AN ANNUAL BASIS BY THE COMPENSATION COMMITTEE AND THE CHAIR OF THE BOARD OF DIRECTORS. COMPENSATION IS BASED ON THE LEVEL OF SKILL REQUIRED FOR THE POSITION, AN EVALUATION OF THE INDIVIDUAL'S ACHIEVEMENT, AND A COMPARISON OF COMPENSATION TO SIMILAR POSITIONS IN THE NON-PROFIT INDUSTRY. THE DETERMINATION OF THE COMPENSATION IS DOCUMENTED BY A COMPENSATION AGREEMENT EXECUTED BY THE CHAIR OF THE BOARD OF DIRECTORS, THE CHAIR OF THE COMPENSATION COMMITTEE, AND THE CEO. FORM 990, PART VI, SECTION C, LINE 19 RX-360'S BYLAWS AND ANTI-TRUST POLICY ARE AVAILABLE ON RX-360'S WEBSITE. ALL OTHER FINANCIAL DOCUMENTS THAT ARE REQUIRED TO BE MADE AVAILABLE TO THE PUBLIC WILL BE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G PROGRAM QUALITY AUDITORS 828,845. PROFESSIONAL FEES 96,891. FORM 990, PART XII, LINE 2C RX-360 HAS IMPLEMENTED THE PROCESS OF HAVING AN AUDIT COMMITTEE AS OVERSIGHT OF THE AUDIT PROCESS. RX-360 EDUCATION AND RESEARCH FOUNDATION PO BOX 40931 PHILADELPHIA PA 19107 845068425 EDUCATION AND RESEARCH PA 501(C)(3) LINE 7 NO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0